Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rociletinib + Trametinib in EGFR+ NSCLC
NCT02580708Phase 2Terminated
- Sponsor
- Clovis Oncology
- Start
- Sep 2015
- Primary completion
- May 2016
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of rociletinib in non-small cell lung cancer (NSCLC), sponsored by Clovis Oncology. Started Sep 2015; status: terminated.
02
Drugs
rociletinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02580708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02580708.